Tiziana Life Sciences Ltd (NASDAQ: TLSA) announced plans to host the Key Opinion Leader Event virtually. The event will have presentations discussing the importance and clinical data on the foralumab intranasal immunotherapy in patients with neurodegenerative diseases.
The company will discuss therapies for Multiple Sclerosis (MS)
Several specialists will describe the existing treatment landscape in neurodegenerative diseases. They will also talk about local potential immunotherapies that can pass the blood-brain barrier. This is vital as not many drugs can cross this barrier in diseases of the brain and spinal cord.
The specialists will also describe the foralumab study of Tiziana and the drugs’ effect on multiple sclerosis (MS). Tiziana had released these results on March 10, 2022.
Tiziana is also testing an intranasal foralumab formulation to treat MS. The data it released showed positive results for the treatment of Secondary Progressive Multiple Sclerosis (SPMS) after six months.
Following the presentation from the specialists, there will be a Q&A session. Interested parties can register to be notified of the presentation and submit their questions on the company website.
Speakers at the event
One of the speakers for the event will be Dr. Howard L. Weiner, who is a Neurology Professor. He also founded the Partners Multiple Sclerosis Center in 2000. The center combines immune monitoring, MRI imaging, and clinical evaluation.
Dr. Weiner was also the first to use cyclophosphamide to treat MS as an immunotherapy for the disease. Moreover, he investigated MS immune abnormalities. This included the role the innate immunity and T cells played in MS.
Dr. Tanuja Chitnis will also speak at the event. She has experience treating adult MS patients and has many publications on the topic. Furthermore, Dr. Chitnis takes part in many MS-related studies to understand its progression in children.
Another speaker at the event will be Dr. Lawrence Steinman. He is a professor of genetics, pediatrics, neurological sciences, and neurology. He investigates the cause of remission and relapses in MS and finding a tolerant vaccine.
Dr. Tarun Singhal is the last presenter at the event. He has board certification for nuclear medicine and neurology. In addition, he has led many projects on molecular imaging. Dr. Singh sees many MS patients and heads PET Imaging, Brigham, and Women’s Hospital.
